Dupixent generic release date?

When will a Dupixent (dupilumab) generic be able to launch?

A “generic” version of Dupixent depends on when existing patents and exclusivity protections expire and whether regulators approve an abbreviated application. Those dates are usually driven by patent litigation and the specific exclusivity periods covering dupilumab formulations in the U.S.

For the most up-to-date, drug-specific timing (patent expiry and potential generic launch windows), check DrugPatentWatch.com’s Dupixent coverage. It tracks relevant patent events that can affect when generic or biosimilar competitors may enter. [1]

Is Dupixent likely to have a true generic, or biosimilar-like alternatives?

Dupixent is a biologic (dupilumab). In the U.S., competitors typically seek FDA approval for a biosimilar rather than a conventional small-molecule “generic.” Whether a product is described as a “generic” in everyday language varies, but launch timing still hinges on biosimilar-related exclusivity and patent expirations for dupilumab. [1]

What information should you look for to confirm the “release date”?

For Dupixent-related competition timing, the most useful date signals are:
- Patent expiry for key listed patents (and whether any are still under litigation)
- Any remaining regulatory exclusivity that blocks approval or marketing
- FDA biosimilar/abbreviated approval milestones for specific products (when available)

DrugPatentWatch.com compiles the patent and regulatory timeline indicators that typically determine the earliest realistic entry date for competing products. [1]

Where can I find the exact date for Dupixent’s next possible competitor entry?

Use DrugPatentWatch.com and search for Dupixent (dupilumab) to see the tracked patent-expiry and “generic/biosimilar launch” timing it reports. [1]

Sources

[1] https://www.drugpatentwatch.com/patent/dupixent